Modifiers of Hearing Impairment in Humans and Mice by Yan, Denise & Liu, Xue-Zhong
  Current Genomics, 2010, 11, 269-278  269 
  1389-2029/10 $55.00+.00  ©2010 Bentham Science Publishers Ltd. 
Modifiers of Hearing Impairment in Humans and Mice 
Denise Yan and Xue-Zhong Liu* 
Department of Otolaryngology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 
Abstract: Lack of penetrance and variability of expression are common findings in nonsyndromic hearing loss with auto-
somal dominant mode of inheritance, but are also seen with recessive inheritance. Now we know that genotype cannot 
necessarily predict phenotype due to the complexity of the genome, the proteome interacting with the transcriptome, and 
the dynamically coupled systems that are involved. The contribution of genetic background to phenotypic diversity re-
flects the additive and interactive (epistasis) effects of multiple genes. Because, individual genes do not act alone but 
rather in concert with many other genes, it is not surprising that, modifier genes are common source of phenotypic varia-
tion in human populations. They can affect the phenotypic outcome of a given genotype by interacting in the same or in a 
parallel biological pathway as the disease gene. These modifier genes modulate penetrance, dominance, pleiotropy or ex-
pressivity in individuals with Mendelian traits and can also be exerted by influencing the severity, the penetrance, the age 
of onset and the progression of a disease. In this review, we focus on modifier genes that specifically affect hearing loss 
phenotypes in humans as well as those described in mice. We also include examples of digenic inheritance of deafness, 
because additive or interactive effects can also result from interaction between two mutant genes. 
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INTRODUCTION 
  Phenotypic variation in heritable
  forms of  hearing im-
pairment has been reported within families [1-4] and in indi-
vidual probands carrying the same genetic
 mutations [5]. The 
heterogeneity of genes causing hearing loss is only one fac-
tor contributing to phenotypic heterogeneity. Mutations in 
one hearing loss- associated gene may also lead to multiple 
phenotypes, which are known as allelism. In addition, phe-
notypic variation may result from physiological interaction 
of environmental factors and / or stochastic developmental 
events, as well as from genetic modifier. 
  Hearing loss (HL) is the most common sensory deficit in 
humans, affecting 1 in 1,000 newborns and over 50 percent 
of individuals 80 years of age or older. The World Health 
Organization (WHO) has estimated in 2005 that, 278 million 
people worldwide have moderate to profound hearing loss in 
both ears (WHO; http://www.who.int/mediacentre/fact-
sheets/fs300/en/index.html). Results of the 2002 National 
Health Interview Survey estimate that nearly 31 million of 
all noninstitutionalized adults (aged 18 and over) in the 
United States have hearing disability [6]. Approximately 
50% of the cases of congenital hearing loss are thought to be 
attributable to genetic causes and the remainder to environ-
mental factors. In a particular population, the relative contri-
bution of the environmental causes may be determined by 
social factors, such as population structure and rates of con-
sanguineous marriages, infection control and neonatal and   
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postnatal medical care provision [7]. Thus, in countries with 
poor health care, environmental causes of deafness may out-
number those attributed to genetics, whereas in developed 
countries, the proportion of cases with a clear environmental 
etiology is likely to decline as better therapies for bacterial 
and viral infections are provided, acoustic trauma in the 
workplace is recognized and prevented, and ototoxic drugs 
are avoided. Though, a major health concern costing more 
than $30 billion annually in lost productivity, special 
education, and medical treatment [8], hearing loss is often 
minimized or ignored. 
  HL is based on ascertainment of three attributes: type of 
hearing loss (the site of pathology in the auditory pathway), 
degree of hearing loss (the extent to which hearing is 
impaired), and configuration of the hearing loss (the 
frequencies affected). There are three basic types of HL: 
conductive hearing loss is usually associated with outer or 
middle ear pathology, while sensorineural hearing loss 
occurs when there is damage to the inner ear (cochlea) or to 
the nerve pathways from the inner ear (retrocochlear) to the 
brain. Mixed hearing loss is a combination of conductive and 
sensorineural HL. Based on age at onset of deafness, HL can 
be described as prelingual or postlingual. Approximately, 
two-third of prelingual cases have a genetic basis [9]. The 
remaining one-third of cases can be attributed to environ-
mental and unidentified genetic factors. In most cases, 
inherited HL is monogenic. In 70% of cases, HL occurs as 
sole defect and is classified as nonsyndromic. In the remain-
ing 30%, the HL is accompanied by other medical or physi-
cal findings and is called syndromic [10]. There are several 
ways in which monogenic hearing loss can be inherited. 
Autosomal recessive non-syndromic hearing loss 
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cases and is typically prelingual, while non-syndromic auto-
somal dominant HL (ADNSHL) accounts for about 20% of 
cases and is most often postlingual. In 2-3 % of cases, the 
inheritance is either X-linked or mitochondrial [11]. 
  The genetic basis of hearing loss is complex. Mutations 
in some genes can lead to both recessive and dominant forms 
of deafness; alternatively, different mutations in the same 
gene may result in syndromic and nonsyndromic deafness 
[12]; and even within a single gene, the same mutation can 
give rise to quite variable phenotypes [13]. In some recessive 
hearing loss cases, the combination of two mutations in dif-
ferent genes from the same functional group may be the 
cause of the hearing loss [13-15]. This phenotypic heteroge-
neity demonstrates how the type of mutation within the gene 
and its allelic combinations can affect the overall clinical 
presentation, complicating therefore the establishment of 
genotype-phenotype correlations. Moreover, recent observa-
tions indicate that the phenotypic heterogeneity observed for 
a given mutation may also be due to the contribution of 
modifier genes. 
   Different genetic sources can account for the wide vari-
ety of phenotypes observed in individuals with hereditary 
hearing loss, including genetic heterogeneity, allelic hetero-
geneity, and genetic background effects or modifier loci. In 
humans, distinguishing among these sources of variability 
can be difficult. However, because of the similarity between 
the human and other mammals’ genomes and due to the con-
servation of the genes during mammalian evolution, the 
identity and location of candidate modifier genes in human 
can be reliably predicted from studies in model organisms. 
Here, we review the evidence for modifier genes that spe-
cifically affect hearing disorders in both humans and mice. 
Because, difference between modifier genes and diginic in-
heritance is not always clear, we have included in this re-
view, several examples of digenic inheritance of deafness 
that have been reported in both humans and mice.  
Ear and Sound Processing 
  The mammalian inner ear is a highly intricate organ and 
is composed of two sensory systems: the cochlea embedded 
in perilymph, processes auditory signals and the vestibular 
apparatus, consisting of the vestibule and semicircular ca-
nals, is responsible for postural equilibrium. While, cochlear 
defects cause hearing loss, vestibular dysfunction, is mani-
fested as vertigo or dizziness in humans and circling behav-
ior in mice [16] and zebrafish [17]. Different cell types can 
be distinguished in the sensory epithelia of the cochlea or the 
Organ of Corti and in the vestibule: sensory cells, known as 
hair cells; supporting cells and neurons. There are two types 
of hair cells; a row of inner hair cells and three rows of outer 
hair cells. The inner hair cells are pure receptor cells that are 
primarily responsible for transmission of signals to the 
acoustic nerve and the auditory cortex. The outer hair cells 
have both sensory and motor capabilities that contribute to 
hearing sensitivity and frequency selectivity by amplifying 
sound reception [18]. Each hair cell has in its apical pole a 
bundle of stereocilia, packed with actin filaments and linked 
to each other at their tips. Stereocilia are the mechanorecep-
tive structure of the hair cells as they deflect in response to 
sound vibration. The stereocilia are bathed by endolymph, 
whereas the basolateral cell surfaces of the hair cells are 
bathed by perilymph. The tectorial membrane is a sheet of 
extracellular matrix that overlies the sensory epithelium of 
the cochlea. Deflection of a stereocilia bundle in response to 
sound waves opens mechanically-gated ion channels, 
resulting in an influx of potassium (K
+) from the potassium-
rich endolymph into the sensory cells. The influx of K
+ ions 
causes a change in membrane potential proportional to the 
intensity of the acoustic stimulus. This depolarization of hair 
cells then activates calcium channels, leading to calcium 
influx into the hair cells. This calcium influx triggers the 
release of neurotransmitters into postsynaptic terminals that 
in turn activate the acoustic nerve. The hair cells are repolar-
ized when the K
+ ions leave these cells via potassium chan-
nels and are taken up by the epithelial supporting cells. The 
K
+ ions are then passively diffused to the stria vascularis
 
through gap junctions and are actively pumped back into the 
endolymph through potassium channels, thereby resetting
 the 
mechanoelectrical transduction system [19-22]. Defect in 
either of these auditory processing components leads to 
hearing impairment. 
Genetic Heterogeneity - A Hallmark of Hereditary Deaf-
ness  
  Hearing is a complex process, thus, it should come as no 
surprise that the causes of hearing loss are also complex and 
that hereditary hearing disorders exhibit a high degree of 
genetic heterogeneity. It is estimated that at least 1% of hu-
man protein-coding  genes (i. e. about 300 genes)  are in-
volved in perception of sound [23], and they are thus poten-
tial candidates to cause hearing loss when mutated. There are 
over 400 distinct syndromes  with deafness as one of the 
components have been described  (www.ncbi.nlm.nih.gov/ 
omim)  and  the underlying genetic defect for many of the 
most common forms have been identified. However, the vast 
majority (>70%) of inherited hearing disorders are non-
syndromic [7]. 
 Despite the fact that the
 genetic basis of hearing loss has 
been studied for  decades, identification of the causative 
genes began only in the 1990s and molecular mechanisms 
underlying deafness have just started
  to be unraveled. The 
main obstacles to successful finding of genetic defects lead-
ing to hearing loss included: (i) inaccessibility of the coch-
lea, being buried within the temporal bone, (ii) extreme ge-
netic heterogeneity, (iii) absence of distinctive clinical fea-
tures for the various gene defects, and (iv) assortative mat-
ing.
 Nevertheless, the past few years have witnessed remark-
able achievements in identifying genes associated with deaf-
ness. The identification of these genes and functional charac-
terization of the proteins they encode has provided a major 
insight into our knowledge of the physiology and patho-
physiology of the auditory system. There are approximately 
113 mapped loci and 51 different genes that have been 
shown to underlie hereditary sensorineural nonsyndromic 
hearing loss (NSHL) in humans (http:webhost.ua.ac.be/ 
hhh/). Among the different loci reported, 46 are autosomal 
dominant, 53 for autosomal recessive and 5 for X-linked 
deafness. In addition, a Y chromosome-linked locus and two 
genes on the mitochondrial genome have to be added to the 
list of genes responsible for NSHL [24,25]. There are mouse 
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for half of them, the link to hearing loss was identified prior 
to or concurrently with their identification in humans [26]. 
There are in addition, over 130 protein-coding genes that 
have not been implicated in deafness in humans thus far have 
been identified as responsible for hearing loss in mice. 
Mouse models of genetic HL have enabled researchers to 
characterize the cellular and molecular deficits involved in 
many of these genetic mutations, including a few models 
with double mutations (i.e., mutations in two different genes 
interact to cause hearing loss, while each mutation alone 
does not). Perhaps more importantly, they have provided 
insight into the normal and impaired auditory system. 
MODIFIERS OF HEARING LOSS IN HUMANS 
  Genetic modifiers are one of the several factors that can 
contribute to the phenotypic diversity of a genetic disorder 
and complicate the genetics of mendelian traits. Products of 
modifier genes may include proteins that physically interact 
with the mutant protein, factors that influence the timing or 
rate of transcription of the mutated gene, factors that affect 
the stability of mutant protein. Modifiers decrease the effects 
attributable to the target gene that is the mendelian variant 
and enhance those attributable to the modifier gene.  
Modifying Factors for the Phenotype Linked to Mito-
chondrial DNA (mtDNA) Mutations 
  Many studies showed that the generation of reactive oxy-
gen species (ROS) and free radicals are involved in the cas-
cade of cochlear events culminating in acoustic trauma [27]. 
Intracellular ROS are primarily generated by the 
mitochondrial electron transport chain, making the 
mitochondria a prime target of oxidative damage. However, 
the high mutation rate in the mtDNA is not only due to the 
oxidative damage, but also caused by the lack of protective 
action by histones and the limited capacity of an efficient 
DNA repair system [28,29]. The mutation rate of mtDNA 
has been estimated to be as much as two orders of magnitude 
greater than that for the nuclear DNA [30]. In the case of 
mtDNA mutations both mutated as well as normal mito-
chondrial may be present within the same cell (hetero-
plasmy) or a particular mitochondrial mutation may be pre-
sent in all mitochondrial DNA molecules of an organism 
(homoplasmy).  
  Various mtDNA mutations causing progressive nonsyn-
dromic hearing loss have been identified. Mutations in the 
12S ribosomal RNA (rRNA) and tRNASer(UCN) genes ac-
count for the most cases of maternally inherited nonsyndro-
mic deafness [31]. Nonsyndromic deafness-associated 
mtDNA mutations occurs often in homoplasmy state or at 
high levels of heteroplasmy, suggesting a high threshold for 
pathogenicity [32]. The human mitochondrial 12S rRNA 
A1555G mutation is the most common and has been associ-
ated with and without aminoglycoside-induced and nonsyn-
dromic deafness in many families of different ethnic back-
grounds [33-39]. It has been detected in 0.6-2.5% of the 
Caucasian population with nonsyndromic hearing loss, and 
the frequency is found particularly high in the Spanish popu-
lation [34]. In the Asian populations, the prevalence of 
A1555G mutation is also high: 2.9% in Chinese [35], 3% in 
Japanese [40] and 5.3% in Indonesia [38]. 
  Phenotypic manifestation of mutation A1555G is ex-
tremely variable, including cases of normal hearing carriers 
[41]. Hearing loss, in affected individuals, varies in several 
respects, including age at onset and severity; for some indi-
viduals, hearing loss is present at birth, whereas others ex-
hibit a slow, progressive hearing loss of adult-onset. Amino-
glycoside antibiotics, mitochondrial haplotypes and nuclear 
modifying genes have been proposed as the three major 
modulators for the phenotypic expression of the deafness-
associated 12S rRNA mutations [31]. 
  In cases of no previous history of exposure to aminogly-
cosides, the A1555G mutation induces a clinical phenotype 
that varies substantially among family members and ranges 
from severe congenital deafness, to moderate progressive 
hearing loss of later onset, to completely normal hearing 
[31]. The penetrance has also been shown different between 
families carrying the A1555G mutation. In some families, 
most of the individuals carrying the A1555G develop hear-
ing loss, but in others, the penetrance can be extremely low 
[39,42]. Functional characterization demonstrate that more 
severe biochemical defects were observed in the mutant 
lymphoblastoid cell lines derived from symptomatic indi-
viduals than from cell lines derived from asymptomatic indi-
viduals in a same family [43]. However, under a constant 
nuclear background, a nearly identical degree of mitochon-
drial dysfunction was observed in cybrid cell lines derived 
from symptomatic and asymptomatic individuals [44]. These 
findings strongly indicate that the A1555G mutation is a 
primary cause of deafness and that nuclear modifier genes 
play a role in modulating the phenotypic expression of the 
hearing loss associated with the A1555G mutation.  
  Several mitochondrial genes (tRNASer(UCN), tRNAGlu, 
tRNAArg, tRNAThr) and a few nuclear genes have subse-
quently been reported as being genetic modifiers [45-48]. 
Members of Arab-Israeli, Spanish and Italian families carry-
ing the A1555G and homozygous for A10S TRMU mutation 
have been shown to exhibit prelingual profound deafness 
[45]. Functional analysis indicated that the homozygous 
A10S mutation in the TRMU gene disrupts the mitochondrial 
tRNA metabolism, specifically lowering the steady-state 
levels of mitochondrial tRNA and thereby contribute to the 
impairment of mitochondrial-protein synthesis [45,46]. Mu-
tations in the GJB2 gene have also been implicated in modu-
lating the severity of hearing loss associated with the 
A1555G mutation. The modulating effect might be explained 
by the inability of cochlear cells to efficiently utilize metabo-
lites for energy production which in turn may affect the nor-
mal turnover rates of gap junction proteins [49]. A possible 
nuclear modifier gene associated with hearing loss without 
exposure to aminoglycosides in subjects with the A1555G 
mutation has been localized to chromosome 8p23.1 [50], but 
the identification of this gene has remained elusive. The mi-
tochondrial transcription factor B1 (TFB1M), as well as the 
human homologs of yeast MTO1 and MSS1 genes, MTO1 
and  GTPBP3, respectively, have also been reported to be 
involved in the process of mitochondrial RNA modification 
[51,52]. However the precise mutation (s) and /or variant (s) 
responsible for the modifier effect of these genes remain to 
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GJB2 ( CX26) Gene Mutations Show Phenotypic Varia-
tion 
 GJB2, which encodes the gap junction protein connexin 
26 (Cx26) is responsible for up to 50% of the cases with 
autosomal recessive non-syndromic sensorineural hearing 
loss (DFNB1) [53]. Cx26 is expressed in the spiral ligament, 
the basal cells of the stria vascularis, various supporting 
cells, and the limbal fibrocytes [54,55]. Cx26 is presumed to 
mediate the recycling of potassium ions that flow into sen-
sory hair cells as part of the transduction current. 
  There are over 100 different mutations of GJB2 that 
cause non-syndromic deafness and a significant difference in 
the frequency and distribution of the mutations have been 
observed in different populations (http://davinci.crg.es/ 
deafness/index.php). Most interestingly, a single mutation, 
35delG, accounts for up to 70% of the Northern and South-
ern European, as well as American Caucasian populations 
with GJB2 mutations, with a carrier frequency ranging from 
1.3 to 2.8% [56,57]. In the Jewish deaf population, the 
167delT, accounts for 40% of the pathologic alleles [58] and 
has 4% carrier frequency among Ashkenazi Jews [59]. The 
235delC mutation is the most prevalent in the Eastern Asian 
(Japanese, Chinese and Korean) populations. The R143W 
mutation has been associated with recessive nonsyndromic 
deafness in Ghana and the W24X, the most common GJB2 
mutation in India, has also been found in high prevalence in 
Slovak and Spanish gypsies (www.gendeaf.org). A series of 
reports have attempted to assess a possible genotype-
phenotype correlations for GJB2 mutations [5,11,60-62]. A 
multicentre study by Snoeckx and colleagues [63] estab-
lishes some genotype- phenotype relationships, including the 
observation that probands with biallelic frameshift or non-
sense mutations had more severe hearing impairment than 
those with biallelic missense mutations. In addition, the 
M34T and V37I variants have shown to induce a mild 
hearing loss when in compound heterozygosity with a 
truncated mutation. Although, the phenotype expression can 
be predicted on the basis of the genotype for most genotypes, 
the correlation could only partly explain the phenotypic vari-
ability. For the majority of these genotypes, a certain degree 
of phenotypic variability has been observed, which was the 
most striking for 35delG homozygous patients. The severity 
of hearing loss in 35delG homozygotes showed significant 
inter- and intrafamilial phenotypic variability, ranging from 
mild or moderate to severe and profound [61]. In a recent 
study, involving a set of 1277 35delG homozygous patients 
from 14 countries, Hilgert and colleagues [64] sought to 
identify modifier genes for connexin 26-related hearing 
impairment. A whole-genome association (WGA) study has 
been performed on 35delG homozygotes by comparing the 
genotypes of mild/moderate cases and profound cases. The 
data suggest that the phenotypic variability in 35delG 
homozygous patients cannot be explained by the effect of 
one major modifier gene and more likely caused by a smaller 
effect of different interacting genes. 
Dominant Modifier DFNM1, A Suppressor of the Pro-
found Hearing Loss Locus DFNB26 
  Homozygosity mapping within consanguineous families 
is a powerful method for identifying genes that modify deaf-
ness phenotypes. In a consanguineous Pakistani family, Ria-
zuddin and colleagues [3] mapped an autosomal recessive 
nonsyndromic hearing loss locus, DFNB26, to chromosome 
4q31. Homozygosity for the DFNB26-linked markers can 
lead to profound congenital deafness. However, there were 7 
unaffected family members who were also homozygous for 
the DFNB26-linked haplotype and thus were nonpenetrant. 
In this rare instance, the family size was sufficiently large to
 
allow the investigators to map DFNM1, a single dominant 
suppressive locus of DFNB26, to
  chromosome 1q24 (near 
D1S2850). Identification and functional analyses of these 2 
genes should reveal the molecular pathophysiology of 
DFNB26 and elucidate the underlying mechanism of 
DFNM1 suppression. Of note, the map location of DFNM1 
is within the 22-cMorgan interval that contains the DFNA7 
locus [65], suggesting that the DFNM1 suppressor phenotype 
and DFNA7 deafness may be two phenotypic variants of the 
same gene. Also, located within the DFNM1  interval, the 
PMX1 (paired mesoderm homeobox) gene that is expressed 
in the cochlea, is a potential candidate gene [66]. 
The ATP2B2 Gene, A Modifier of CDH23 Deafness 
 CDH23 encodes cadherin
  23, a putative calcium-
dependent adhesion molecule required
  for proper morpho-
genesis of cilia of the hair cells of the inner ear. Mutations in 
the Cadherin 23 gene (CDH23) have been associated with 
Usher syndrome type 1D, and DFNB12, a form of autosomal 
recessive hearing loss [67]. In homozygous waltzer mice, 
mutations in Cdh23 cause profound deafness
 and vestibular 
dysfunction [68]. Interestingly, subsequent evidence shows 
that variants in Cdh23 also underlie the age related hearing 
loss (Ahl) locus and contribute to differences in onset and 
severity of AHL among inbred mouse strains [69]. Thus, 
Cdh23 may be an important gene that may not only underlie 
certain forms of congenital deafness but also age-related 
hearing loss and has the potential to genetically interact with 
other deafness genes to affect hearing. The finding that vari-
ants of the Atp2b2 gene, which encodes a calcium pump in 
the plasma membrane, module the severity of hearing loss in 
waltzer mice [70] would add further support to the conten-
tion. A nucleotide change in the human ATP2B2 gene was 
later shown to exacerbate hearing loss in individuals homo-
zygous for a CDH23 mutation, similar to the Atp2b
2dfw-2J–
Cdh23
753A/G interaction affecting hearing in mice, in a con-
sanguineous family of the European descent [71]. In this 
family, five adult siblings expressed variable degrees of 
hearing loss differentially affecting the higher frequencies. 
While all individuals with hearing loss were homozygous for 
a missense mutation (F1888S) in CDH23, those subjects 
with the hearing loss affecting all frequencies were also het-
erozygous for a missense mutation (V586M) in plasma-
membrane calcium pump PMCA2, which is encoded by 
ATP2B2. Individuals with hearing loss in the higher frequen-
cies but with normal thresholds in the lower range had the 
normal 586V allele. Thus, the 586M allele of ATP2B2 seems 
to have a clear modifying effect when combined with the 
CDH23 mutation. Interestingly, heterozygosity
  for the 
ATP2B2 variant was not sufficient to cause hearing loss
 — 
an observation that is typical of most modifier genes:
 they 
generally have detectable effects on the trait, only in the 
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MODIFIERS OF HEARING LOSS IN MICE 
  Because of their diverse genetic background, inbred 
strains of mice manifest strikingly different patterns of back-
ground pathology. A specific phenotype can even vary in 
one mouse strain or disappear in another strain. To detect a 
modifier it is required to cross the mutant allele with differ-
ent inbred strains to permit random segregation of the mutant 
and modifying alleles. Analyses of appropriate linkage 
crosses and congenic lines can be used for the mapping of 
modifier loci, and the major modifying loci can be identified 
by positional-candidate gene method. In the following sec-
tion, we report an evidence for modifiers of hearing impair-
ment in mice.  
Modifiers of Deaf Waddler (mdfw) 
  Mice homozygous for the  deaf waddler mutation 
(dfw/dfw), localized on chromosome 6, exhibit circling be-
havior as a result of vestibular dysfunction in addition to 
congenital hearing loss. A plasma membrane ATPase type 2-
Ca
2+ transporter pump (Atp2b2) has been identified as the
 
gene responsible for the dfw mutation. Several spontaneous 




wriggle mouse Sagami (Atp2b2
wri), and tommy (Atp2b2
tmy). 
The dfw mutant results from a single A->G nucleotide transi-
tion leading to a glycine to serine substitution at residue 283 
of PMCA2; in dfw-2J, a 2 bp deletion causes a frameshift 
and premature stop codon after residue 471 of PMCA2; in 
wri, a G->A transition replaces a glutamate by a lysine in a 
highly conserved region in the fourth transmembrane domain 
of PMCA2; and in tmy, another G->A transition generates a 
change from glutamate to lysine in the ATP binding domain 
of PMCA2. The vestibular abnormalities in dfw mice are less 
severe than in dfw-2J, wri, or Atp2b2-null mice, which ex-
press no functional PMCA2. The dfw mutation results in a 
reduction in Ca
2+ transport activity to 30% compared to that 
of the wild-type activity of PMCA2 [72]. The localization of 
the ATP2B2 protein to stereocilia and basolateral wall of 
hair cells, suggests that it provides the means to remove cal-
cium from both auditory and vestibular
 hair cells [73]. The 
onset and severity of hearing loss in heterozygote Atp2b2
+/- 
vary with the genetic background. This variation is attribut-
able to a locus named modifier of deaf waddler (mdfw), 
which maps to mouse chromosome 10, near two other loci 
affecting hearing in mice: the ahl locus and the mouse muta-
tions waltzer (v). There are two known mutant alleles of 
mdfw: the CAST/Ei – derived mdfw allele protects dfw/+ 
mice from deafness in a dominant
 fashion, whereas the re-
cessive cBy-derived mdfw allele permits hearing loss to
 oc-
cur in dfw/+ mice. A fine structure map analysis has subse-
quently suggested allelism between mdfw and Cdh23
v  
[74] and a single nucleotide polymorphism in Cdh23, 
Cdh23
753A/G associated with Ahl1 was identified as the mo-
lecular basis of mdfw [70]. The hypomorphic Cdh23
753A al-
lele causes skipping of exon 7 leading to an in-frame dele-
tion of 43 amino acids at the extracellular amino-terminus. 
The Cdh23
753A variant is generally associated with increased 
susceptibility to AHL but the predisposition conferred by 
Cdh23
753A depends on the effects of several strain-specific 
genetic factors, including the mitochondrial mutation mt-
Tr
9827ins8 and the ahl2 and ahl3 loci [70]. The Cdh23 locus 
has also been shown to modify the deafness caused by the 
Mass1
frings mutation in BUB/BnJ strain mice and can account 
for the phenotypic manifestations differences observed be-
tween Frings (Cdh23
753G) and BUB/BnJ (Cdh23
753A) [75,76]. 
Modifiers of Deafness in the tub Mouse 
  A recessive mutation in the tub gene causes obesity, 
early-onset cochlear and retinal degeneration in tubby mice 
[77]. The gene encodes a member of the Tubby family of 
bipartite transcription factors [78]. The phenotypes observed 
in tubby mice are affected by the genetic background [77], 
but the exact mechanisms by which the tub allele causes the 
tubby phenotypes is unknown. A major dominant modifier 
locus of tubby
  hearing 1 (moth1) has been identified on 
chromosome 2 by linkage
 analysis [77]. On the coisogenic 
C57BL/6J background, homozygous tubby mice suffered 
from profound deafness. When crossed onto the AKR/J and 
CAST/Ei backgrounds, tub/tub exhibit a wide spectrum of 
hearing thresholds ranging from deafness to a complete res-
cue. Amino acid polymorphisms in the microtubule-
associated protein 1A
 gene (Mtap1a) have subsequently been 
found responsible for the modifying effect of moth1 [79]. 
The Moth1 modifier influences only the hearing phenotype 
of tubby mice and has no effect on any other phenotypic 
manifestations of the tubby mutation, such as retinal degen-
eration and obesity. As MTAP1A may be involved in traf-
ficking of synaptic components from the cytosol to the syn-
aptic junction [80,81], it was suggested that the function of 
Tub may be associated
 with synaptic function between hair 
cells and cochlear neurons [79].  
DIGENIC INHERITANCE - A CAUSE OF SOME 
FORMS OF DEAFNESS 
  Most cases of genetic deafness result from mutations at a 
single gene, but an increasing number of examples are being 
recognized in which recessive mutations at two loci are in-
volved. In digenic inheritance, mutations in each of two un-
linked genes are present in a single individual, and the com-
bination of the two genetic hits causes a disease phenotype 
that is not apparent when an individual carries only one of 
these gene alterations. This mechanism complicates genetic 
evaluation and counseling, but provides an explanation for 
individuals with a heterozygote mutation in a deafness gene 
who, for previously unknown reasons, are deaf. Because, 
difference between modifier genes and diginic inheritance is 
not always clear, we have included in this review several 
examples of digenic inheritance of deafness that have been 
reported in both humans and mice. Given the high degree of 
similarity between mouse and human genomes, it came as no 
great surprise that some forms of digenic inheritance and 
genetic modifications are found in both species.  
  Digenic interactions are known to be an important cause 
of deafness in patients who carry a single mutation at the gap 
junction protein GJB2 (connexin 26) along with a deletion 
involving the functionally related GJB6 (connexin 30). The 
deafness of individuals heterozygous for GJB2 mutations has 
been associated with in trans heterozygosity for GJB6 gene 
deletions [82,83]. Double heterozygous mice for both Gjb2 
and Gjb6 mutations (Gjb2
+/ Gjb6
+/ double heterozygotes) 
exhibit a moderate hearing impairment and reduced en-274    Current Genomics, 2010, Vol. 11, No. 4  Yan and Liu 
docochlear potential compared with single heterozygotes 
[84], in contrast with the phenotype observed in humans, 
wherein most double heterozygotes for del(GJB6-
D13S1830) and a GJB2 mutation have severe or profound 
hearing impairment [82,83,85-89]. Interestingly, the 
del(GJB6-D13S1830) allele is the most frequent in Spain, 
France, the United Kingdom, Israel, and Brazil, accounting 
for 5.0–9.7% of all the DFNB1 alleles [62,90] and this find-
ing provided an explanation for the deafness in as many as 
30% to 70% of affected GJB2 heterozygotes in those coun-
tries. However, this large deletion has not been detected in 
Turkish, Italian, Austrian, Greek Cypriot and Chinese non-
syndromic hearing loss patients [90-94], suggesting that 
other mutations, both within DFNB1 and elsewhere may be 
involved in epistatic interactions with GJB2. We recently 
provided an evidence that mutations in the Cx26 and Cx31 
genes can interact to cause hearing loss in digenic heterozy-
gotes. Direct physical interaction of the two proteins is sup-
ported by data showing that Cx26 and Cx31 have overlap-
ping expression patterns in the cochlea and that in vitro the 
two connexins were able to co-assemble in the same junction 
plaque [15]. 
 Recessive  mutations  in  genes coding for cadherin  23 
(Cdh23)  and  protocadherin
  15 (Pcdh15) cause deafness  in 
both mice and humans. Given the similarities in function and 
effect of pathogenic mutations of Cdh23 and Pcdh15, we 
assessed whether there is functional interaction between the 
two genes by generating double mutant mice for Cdh23 and 
Pcdh15 (14). Our data showed that mice doubly heterozy-
gous
  for  Cdh23
v-2J and  Pcdh15
av-3J mutations  exhibit age 
related deafness and
 abnormal stereocilia in outer and inner 
hair cells of the organ
 of Corti, whereas single heterozygotes 
lack
 this pathology. We also had evidence of a digenic in-
heritance of mutations in CDH23 and PCDH15 in three un-
related families with USH1 phenotype. Other additional 
cases of digenic inheritance of deafness have been reported 
in humans including an interaction between the GJB2 and 
the mtDNA 12S rRNA (MTRNR1) gene, in which the hear-
ing loss associated with the 1555A>G mitochondrial muta-
tion is more severe in patients who also are heterozygous for 
the GJB2 mutation [49]. Interaction between mutant alleles 
at the DFNA12 and DFNA2 loci was proposed to explain the 
phenotype variation in an extended Swedish family with 
nonsyndromic progressive bilateral sensorineural hearing 
loss. Analysis of the phenotypes and haplotypes shared by 
the affected individuals indicate that the two loci are respon-
sible for the hearing impairment in the family and the pres-
ence of both of them is associated with a more severe hear-
ing loss as compared to the hearing loss caused by each of 
the loci separately [95]. In a family of Jewish Yemenite ori-
gin, a mutation in MYO7A appears to exacerbate deafness in 
individuals with two mutant USH3 alleles, suggesting an 
interaction between the gene products [96]. USH3 encodes 
clarin-1, an integral membrane protein expressed in cochlear 
hair cells and ganglion cells, suggesting that the USH3A–
MYO7A interaction may play a role in hair cell synapses 
[97]. 
STRATEGIES FOR IDENTIFICATION OF MODI-
FIER GENES 
  Several approaches can be adopted for mapping and 
identifying the modifier genes for human disorders. The 
family-based linkage strategy can be applied to investigate 
the phenotypic difference among affected individuals from 
multiplex families with significant intrafamilial variation. 
Using this method, the DFNM1 locus, a modifier of 
DFNB26-linked deafness was identified [3] and the deafness 
phenotype associated with the 1555A>G mutation in 
MTRNR1 was shown to be modified by three different genes: 
MTO1, TFB1M and GTPBP3 [51,52]. Another approach is 
to perform disease-marker association studies in unrelated 
patients. The ability to genotype hundreds of thousands of 
single-nucleotide polymorphisms (SNPs) covering the 
complete genome makes the whole-genome association 
(WGA) scans feasible due to innovative combinations of 
assays and array platforms. However, WGA studies are 
costly, if samples are individually genotypes. A cost effec-
tive solution is to genotype pooled DNA on SNP microar-
rays and screen for allelic frequency differences between 
cases and controls (or low versus high groups). This ap-
proach has been used successfully to identify SNPs associ-
ated with complex disorders [98-102] and recently applied to 
identify modifier genes for Connexin 26-related hearing 
impairment in a set of 1277 35delG homozygous patients 
from 14 countries. The study suggests that the phenotypic 
variability in 35delG homozygous patients cannot be 
explained by the effect of one major modifier gene [64]. A 
limitation of pooling-based WGA studies is that they are 
only effective in identifying common variations with a large 
effect on the disease. 
  In mice, the most efficient strategy for mapping modifier 
genes is to cross parental inbred strains that carry the causa-
tive mutation and show a difference in phenotype. To ascer-
tain potentially dominant modifier effects, homozygous mu-
tants are generally used to generate the F1 hybrids, which 
leads to a genetically uniform population. Two genotypes in 
F1 hybrids are obtained, which provides information of ef-
fects of genetic background that are not due to the mutant 
allele, if a cross is initiated with heterozygous mutants. An 
intercross of F1 hybrid carriers produces a higher degree of 
allele combinations and increases the chance to detect phe-
notypic differences and epistatic interactions. For dominance 
effects, in which a modifier affects the mutant allele only 
when in a homozygous state, the backcross is more suitable 
as it yields a larger phenotypic population for linkage detec-
tion. The intercrosses (F2 animals) and backcrosses (N2 
animals) progeny are assessed for phenotypic variation. 
Standard quantitative trait loci (QTL) analysis methods
 can 
then be applied to map the modifier loci in F2 animals with 
modified phenotypes [103]. The use of animals with extreme 
phenotypes for initial linkage analysis will maximize infor-
mation without affecting detection sensibility [104]. If a ma-
jor modifying locus is detected, a combination of conven-
tional fine
 mapping in a large F2 intercross and progeny test-
ing can be used to narrow the genetic interval to provide a 
basis for positional cloning [77,79]. When the fraction of the 
phenotypic variance is due to multiple loci, production of 
congenic
 lines may be needed to identify the modifier loci. 
Crosses for fine-resolution mapping may subsequently per-
form on congenic
 line harboring a phenotypic effect of the 
modifier locus greater than the non-genetic variation. Con-
ventional positional
  cloning strategy can then be applied, 
once a high-resolution map
  has been obtained [103,105]. Modifiers of Hearing Impairment in Humans and Mice  Current Genomics, 2010, Vol. 11, No. 4    275 
Current technology, such as gene expression microarray 
analysis may be combined with the use of congenic lines to 
directly
 identify a mutant modifier allele or point to the mis-
regulation




  The past decade has witnessed great advancements in our 
knowledge of the structure and function of genes involved in 
deafness. However, many of these genes do not follow the 
rules of the typical Mendelian expression patterns of inheri-
tance and may be subject to the effects of modifier genes. In 
this review, we have presented the examples of modifier loci 
and/or their genes for hereditary hearing loss that have been 
discovered in both humans and mice. While chromosomal 
location of some modifier effects has been identified, clon-
ing of modifier genes still remains to be a difficult task. The 
challenge of molecular mapping and identification of modi-
fier loci will propel development of newer strategies. The 
elucidation of modifier genes will provide insight into mo-
lecular and cellular pathways and mechanisms of genetic 
interactions involved in auditory systems. Furthermore, it 
may also be helpful in designing new therapeutics that target 
expression of modifiers. 
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ABBREVIATIONS 
ADNSHL  = Autosomal dominant non-syndromic hear-
ing loss 
ARNSHL  =  Autosomal recessive non-syndromic hearing 
loss 
CX26 =  Connexin  26 
DFNB  =  Autosomal deafness nonsyndromic reces-
sive locus 
DFNM  =  Deafness nonsyndromic modifier 
GTPBP3  =  GTP binding protein 3 (mitochondrial) 
HL =  Hearing  loss 
K
+ =  Potassium 
MTO1  = Mitochondrial translation optimization 1 
homolog (S. cerevisiae) 
mtDNA =  Mitochondrial  DNA 
NSHL =  Nonsyndromic  hearing  loss 
QTL =  Quantitative  trait  loci 
ROS  =  Reactive oxygen species 
rRNA =  Ribosomal  RNA 
SNPs =  Single-nucleotide  polymorphisms 
TFB1M  =  Transcription factor B1, mitochondrial 
tRNASer  =  Transfer RNA for serine 
tRNAGlu  =  Transfer RNA for glutamic acid 
tRNAArg  =  Transfer RNA for arginine 
tRNAThr  =  Transfer RNA for threonine 
TRMU =  tRNA  5-methylaminomethyl-2-thiouridylate 
methyltransferase 
WGA =  Whole-genome  association 
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